A. Saldivar

发表

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

A. Molla, S. Vasavanonda, D. Norbeck, 1998, Journal of medicinal chemistry.

Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease

S. Vasavanonda, D. Norbeck, D. Kempf, 1995 .

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

S. Vasavanonda, D. Norbeck, D. Kempf, 1996 .

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.

S. Vasavanonda, D. Kempf, H. Sham, 1993, Journal of medicinal chemistry.

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

A. Molla, S. Vasavanonda, D. Norbeck, 2001, Bioorganic & medicinal chemistry letters.

Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease

A. D. Rodrigues, S. Muchmore, A. Molla, 1997 .

Facile synthesis of potent HIV-1 protease inhibitors containing a novel pseudo-symmetric dipeptide isostere

D. Norbeck, D. Kempf, H. Sham, 1993 .

Potent HIV-1 protease inhibitors with antiviral activities in vitro.

S. Vasavanonda, D. Norbeck, D. Kempf, 1991, Biochemical and biophysical research communications.

Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.

S. Vasavanonda, H. Sham, T. Robins, 1995, Biochemical and biophysical research communications.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

V. Stoll, S. Vasavanonda, D. Norbeck, 2005, Bioorganic & medicinal chemistry letters.

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.

S. Vasavanonda, D. Norbeck, H. Sham, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

S. Vasavanonda, D. Norbeck, D. Kempf, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

A. Molla, S. Vasavanonda, N. Lyons, 1996, Journal of medicinal chemistry.

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

S. Vasavanonda, D. Norbeck, D. Kempf, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.

A. Molla, S. Vasavanonda, D. Norbeck, 1996, Biochemical and Biophysical Research Communications - BBRC.

Pseudo‐symmetrical difluoroketones

S. Vasavanonda, D. Norbeck, D. Kempf, 1993, FEBS letters.